003220 — Daewon Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩320bn
- KR₩434bn
- KR₩527bn
- 68
- 67
- 46
- 68
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 18,798 | 10,521 | 54,820 | 47,006 | 30,030 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 48,564 | 42,312 | 54,595 | 66,847 | 73,387 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 121,548 | 117,276 | 180,377 | 207,284 | 209,293 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 157,636 | 157,252 | 166,674 | 158,912 | 160,092 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 327,532 | 335,214 | 429,580 | 453,550 | 507,998 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 61,740 | 56,017 | 102,076 | 128,146 | 182,690 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 122,591 | 121,276 | 210,281 | 202,603 | 241,799 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 204,941 | 213,938 | 219,299 | 250,947 | 266,199 |
Total Liabilities & Shareholders' Equity | 327,532 | 335,214 | 429,580 | 453,550 | 507,998 |
Total Common Shares Outstanding |